Literature DB >> 12644349

"Routine invasive" versus "selective invasive" approaches to non-ST-segment elevation acute coronary syndromes management in the post-stent/platelet inhibition era.

William E Boden1.   

Abstract

Is a "routine invasive" or "selective invasive" strategy the best approach for patients with non-ST-segment elevation acute coronary syndrome (ACS)? A "selective invasive" strategy incorporates ischemia-guided use of aggressive medical therapy followed by angiography and revascularization for angina or stress-induced myocardial ischemia. The "routine invasive" strategy (cardiac catheterization followed by percutaneous coronary intervention within 24 to 48 h of symptom-onset) is frequently employed, but no randomized, controlled trials have demonstrated improved clinical outcomes. Recently, the second Fragmin and fast Revascularization during InStability in Coronary artery disease (FRISC-II) and the Treat angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction (TACTICS TIMI-18) trials found significant reductions in death, recurrent myocardial infarction, or hospitalization for biomarker-positive ACS. Also, the third Randomized Intervention Trial of unstable Angina (RITA-3) recently reported a halving of refractory angina and reduction in the use of antianginal medication with early intervention. Early trials failed to demonstrate the superiority of the "routine invasive" approach, presumably because of fewer revascularizations, unavailability of stents, and more recent use of glycoprotein IIb/IIIa inhibitors and low-molecular-weight heparins. The FRISC-II, TACTICS TIMI-18, and RITA-3 studies indicate that higher-risk patients benefit from early revascularization, but that aggressive antiplatelet, antithrombin, and anti-ischemic therapy are also important. While all three trials support an "early invasive" approach in intermediate- and high-risk patients, other trials support a more "conservative" approach in those without electrocardiographic changes or enzyme elevations. Optimal management should incorporate both strategies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12644349     DOI: 10.1016/s0735-1097(02)02963-7

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  5 in total

1.  Validation of the Thrombolysis In Myocardial Infarction (TIMI) risk index for predicting early mortality in a population-based cohort of STEMI and non-STEMI patients.

Authors:  Pamela J Bradshaw; Dennis T Ko; Alice M Newman; Linda R Donovan; Jack V Tu
Journal:  Can J Cardiol       Date:  2007-01       Impact factor: 5.223

Review 2.  [Myocardial infarct and unstable angina pectoris: diagnostics and therapy].

Authors:  M Weber; C Hamm
Journal:  Internist (Berl)       Date:  2007-04       Impact factor: 0.743

3.  Optimal management of platelet function after coronary stenting.

Authors:  Seung-Jung Park; Seung-Whan Lee
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-02

4.  Comparison of outcomes in ST-segment depression and ST-segment elevation myocardial infarction patients treated with emergency PCI: data from a multicentre registry.

Authors:  Jiri Knot; Petr Kala; Richard Rokyta; Josef Stasek; Boyko Kuzmanov; Ota Hlinomaz; Jan Bĕlohlavek; Fili P Rohac; Robert Petr; Dana Bilkova; Slavejko Djambazov; Mladen Grigorov; Petr Widimsky
Journal:  Cardiovasc J Afr       Date:  2012-10       Impact factor: 1.167

5.  Outcomes in patients with non-ST-elevation acute coronary syndrome randomly assigned to invasive versus conservative treatment strategies: a meta-analysis.

Authors:  Ying-Qing Li; Na Liu; Jian-Hua Lu
Journal:  Clinics (Sao Paulo)       Date:  2014-06       Impact factor: 2.365

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.